The Role of PET and SPECT Imaging in Prostate Cancer Targeted Alpha Therapy: When and How?
This review discusses the current state of Targeted Alpha Therapy (TAT) in prostate cancer, particularly in mCRPCT (metastatic castration-resistant prostate cancer). This review describes the widely used Radium-223 and the novel trend in the TAT field with a special focus on prostate-specific membra...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-02-01
|
| Series: | Applied Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-3417/13/3/1890 |
| _version_ | 1797625138418548736 |
|---|---|
| author | Viviana Frantellizzi Maria Ricci Andrea Cimini Luca Filippi Miriam Conte Maria Silvia De Feo Giuseppe De Vincentis |
| author_facet | Viviana Frantellizzi Maria Ricci Andrea Cimini Luca Filippi Miriam Conte Maria Silvia De Feo Giuseppe De Vincentis |
| author_sort | Viviana Frantellizzi |
| collection | DOAJ |
| description | This review discusses the current state of Targeted Alpha Therapy (TAT) in prostate cancer, particularly in mCRPCT (metastatic castration-resistant prostate cancer). This review describes the widely used Radium-223 and the novel trend in the TAT field with a special focus on prostate-specific membrane antigen (PSMA)-based alpha therapy. With this in-depth discussion on the growing field of PSMA-based alpha therapy, we aim also to analyze the most useful diagnostic tools in the patient selection and in the treatment monitoring. We explored the diagnostic tools used in clinical practice and in research settings in order to clarify the imaging procedures that may support the PSMA-based TAT management, including both the patient’s selection and the therapy response monitoring, with a special focus on diagnostic PSMA-PET/CT imaging. Further multicenter trials are needed, but a better understanding of the strengths and limitations of molecular imaging in PSMA-based TAT management may help in creating an effective therapeutic algorithm for mCRPC and designing a rational approach to treatment. |
| first_indexed | 2024-03-11T09:52:32Z |
| format | Article |
| id | doaj.art-e6fb27a7364d4bd4be1df6e0723f3245 |
| institution | Directory Open Access Journal |
| issn | 2076-3417 |
| language | English |
| last_indexed | 2024-03-11T09:52:32Z |
| publishDate | 2023-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Applied Sciences |
| spelling | doaj.art-e6fb27a7364d4bd4be1df6e0723f32452023-11-16T16:11:49ZengMDPI AGApplied Sciences2076-34172023-02-01133189010.3390/app13031890The Role of PET and SPECT Imaging in Prostate Cancer Targeted Alpha Therapy: When and How?Viviana Frantellizzi0Maria Ricci1Andrea Cimini2Luca Filippi3Miriam Conte4Maria Silvia De Feo5Giuseppe De Vincentis6Department of Radiological Sciences, Oncology and Anatomo-Pathology, Sapienza, University of Rome, 00161 Rome, ItalyNuclear Medicine Unit, Cardarelli Hospital, 86100 Campobasso, ItalyNuclear Medicine Unit, St. Salvatore Hospital, 67100 L’Aquila, ItalyDepartment of Nuclear Medicine, Santa Maria Goretti Hospital, 04100 Latina, ItalyDepartment of Radiological Sciences, Oncology and Anatomo-Pathology, Sapienza, University of Rome, 00161 Rome, ItalyDepartment of Radiological Sciences, Oncology and Anatomo-Pathology, Sapienza, University of Rome, 00161 Rome, ItalyDepartment of Radiological Sciences, Oncology and Anatomo-Pathology, Sapienza, University of Rome, 00161 Rome, ItalyThis review discusses the current state of Targeted Alpha Therapy (TAT) in prostate cancer, particularly in mCRPCT (metastatic castration-resistant prostate cancer). This review describes the widely used Radium-223 and the novel trend in the TAT field with a special focus on prostate-specific membrane antigen (PSMA)-based alpha therapy. With this in-depth discussion on the growing field of PSMA-based alpha therapy, we aim also to analyze the most useful diagnostic tools in the patient selection and in the treatment monitoring. We explored the diagnostic tools used in clinical practice and in research settings in order to clarify the imaging procedures that may support the PSMA-based TAT management, including both the patient’s selection and the therapy response monitoring, with a special focus on diagnostic PSMA-PET/CT imaging. Further multicenter trials are needed, but a better understanding of the strengths and limitations of molecular imaging in PSMA-based TAT management may help in creating an effective therapeutic algorithm for mCRPC and designing a rational approach to treatment.https://www.mdpi.com/2076-3417/13/3/1890prostate cancertargeted alpha therapy223-radium<sup>225</sup>Ac-PSMAimagingSPECT/CT |
| spellingShingle | Viviana Frantellizzi Maria Ricci Andrea Cimini Luca Filippi Miriam Conte Maria Silvia De Feo Giuseppe De Vincentis The Role of PET and SPECT Imaging in Prostate Cancer Targeted Alpha Therapy: When and How? Applied Sciences prostate cancer targeted alpha therapy 223-radium <sup>225</sup>Ac-PSMA imaging SPECT/CT |
| title | The Role of PET and SPECT Imaging in Prostate Cancer Targeted Alpha Therapy: When and How? |
| title_full | The Role of PET and SPECT Imaging in Prostate Cancer Targeted Alpha Therapy: When and How? |
| title_fullStr | The Role of PET and SPECT Imaging in Prostate Cancer Targeted Alpha Therapy: When and How? |
| title_full_unstemmed | The Role of PET and SPECT Imaging in Prostate Cancer Targeted Alpha Therapy: When and How? |
| title_short | The Role of PET and SPECT Imaging in Prostate Cancer Targeted Alpha Therapy: When and How? |
| title_sort | role of pet and spect imaging in prostate cancer targeted alpha therapy when and how |
| topic | prostate cancer targeted alpha therapy 223-radium <sup>225</sup>Ac-PSMA imaging SPECT/CT |
| url | https://www.mdpi.com/2076-3417/13/3/1890 |
| work_keys_str_mv | AT vivianafrantellizzi theroleofpetandspectimaginginprostatecancertargetedalphatherapywhenandhow AT mariaricci theroleofpetandspectimaginginprostatecancertargetedalphatherapywhenandhow AT andreacimini theroleofpetandspectimaginginprostatecancertargetedalphatherapywhenandhow AT lucafilippi theroleofpetandspectimaginginprostatecancertargetedalphatherapywhenandhow AT miriamconte theroleofpetandspectimaginginprostatecancertargetedalphatherapywhenandhow AT mariasilviadefeo theroleofpetandspectimaginginprostatecancertargetedalphatherapywhenandhow AT giuseppedevincentis theroleofpetandspectimaginginprostatecancertargetedalphatherapywhenandhow AT vivianafrantellizzi roleofpetandspectimaginginprostatecancertargetedalphatherapywhenandhow AT mariaricci roleofpetandspectimaginginprostatecancertargetedalphatherapywhenandhow AT andreacimini roleofpetandspectimaginginprostatecancertargetedalphatherapywhenandhow AT lucafilippi roleofpetandspectimaginginprostatecancertargetedalphatherapywhenandhow AT miriamconte roleofpetandspectimaginginprostatecancertargetedalphatherapywhenandhow AT mariasilviadefeo roleofpetandspectimaginginprostatecancertargetedalphatherapywhenandhow AT giuseppedevincentis roleofpetandspectimaginginprostatecancertargetedalphatherapywhenandhow |